bluebird bio Announces Data Demonstrating First Four Patients with...

In the first four subjects, each of whom had at least three months of follow up, treatment with LentiGlobin BB305 drug product resulted in sufficient hemoglobin production to reduce or eliminate the need for transfusion support among patients with beta-thalassemia major who would otherwise require chronic blood transfusions. These data include the first five subjects treated in bluebird bio's ongoing Phase 1/2 Northstar Study and the first three subjects from its HGB-205 study.

http://ift.tt/1ucrvDc